Certolizumab is reduced in Crohn's disease relative to the efficacy | Plikli CMS
1
Certolizumab is reduced in Crohn's disease relative to the efficacy observed with adalimumab [24, 25], which suggests that Fc-mediated effector functions may be important. Binding of mAbs to FcRn affects clearance, so a similarity assessment of biosimilars should also include sensitive methods to assess binding to FcRn. ABP 501 was shown to have similar binding to FcRn as compared with adalimumab.

Comments

Who Upvoted this Story

What is Plikli?

Plikli is an open source content management system that lets you easily create your own user-powered website.

Latest Comments